We are proud to have another publication in WM: “Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study,” (Journal of Clinical Oncology, 21/7/2023)
Our Website only uses cookies necessary for user interaction with its content. As long as you decide to use this website you consent to the use of cookies.AcceptMore
The session has ended for security reasons. Tap anywhere to reconnect with Hub UoA
The session has ended for security reasons.